| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Director | President & CEO
3 companies
Peter G Traber last filed a Form 4 in September 2023, as Chief Medical Officer at RNAC. The filings on record cover 3 companies. Peter G Traber's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Peter G Traber a middling insider score of 59/100, based on 11 past trades. Over a 12-month horizon, 54.5% of those trades were profitable, with an average 12-month return of -4.3%.
At the last filing, the largest reported position was 451,826 shares of RNAC. Net of sales, the RNAC filings show accumulation of 74,206 shares.
Peter G Traber has 37 Form 4 filings on record from January 2015 to September 2023, across 3 companies: Chief Medical Officer at Cartesian Therapeutics (RNAC), 2020–2023; Director at Lisata Therapeutics (LSTA), 2015–2022; President & CEO at Galectin Therapeutics (GALT), 2015–2018.
The 51 reported transactions were 16 stock awards, 15 option or other derivative awards, 10 open-market sales and 8 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $373K and 7 sales worth about $1.2M.
The largest open-market purchase was 40,000 shares of RNAC at an average $3.24 on December 14, 2020, about $129K.
The largest open-market sale was 100,000 shares of GALT at an average $7.51 on June 13, 2018, about $751K.
Shares as reported in the last Form 4 for each company; the most recent is from September 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2023 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Sell | 705 | $1.06 | $747.30 | -0.2% | -30.9% | -50.2% | |
| Jan 5, 2023 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Sell | 11,644 | $1.13 | $13,185.32 | -2.5% | +12.1% | -46.3% | |
| Jan 5, 2022 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Sell | 3,226 | $3.09 | $9,955.11 | -1.3% | -56.3% | -61.6% | |
| Dec 10, 2021 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Sell | 4,083 | $2.99 | $12,195.51 | -2.4% | -41.9% | -58.8% | |
| Oct 13, 2021 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Sell | 3,636 | $4.39 | $15,962.04 | -2.3% | -35.4% | -63.4% | |
| May 26, 2021 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Buy | 20,000 | $3.99 | $79,850.00 | +17.3% | -1.5% | -82.9% | |
| May 25, 2021 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Buy | 17,500 | $3.37 | $58,897.50 | +17.9% | +14.8% | -80.2% | |
| Mar 18, 2021 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Buy | 20,000 | $4.51 | $90,295.00 | +25.6% | +11.4% | -63.6% | |
| Dec 14, 2020 | RNAC Cartesian Therapeutics, Inc. | Chief Medical Officer | Buy | 40,000 | $3.24 | $129,424.00 | New | - | - | |
| Jun 13, 2018 | GALT Galectin Therapeutics Inc | President & CEO | Sale+OE | 100,000 | $7.51 | $751,000.00 | -48.2% | - | - |